QT-219C

N/A

Report date: 2026/05/18 20:02:07

Base Information

Drug NameQT-219C

Drug Alias NameQT-219CQT-219CX

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > Allogeneic

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsB-cell maturation protein modulatorsT lymphocyte replacements

TargetsB-lymphocyte antigen CD19B-cell maturation protein

Therapy Area/IndicationsAnemia, Hemolytic, Autoimmune

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesThe Second Hospital Of Anhui Medical University

China Registration ClassN/A

Develop Information

Active CompaniesThe Second Hospital Of Anhui Medical University

Inactive CompaniesN/A

Active IndicationsAnemia, Hemolytic, Autoimmune

Inactive IndicationsN/A

Other Information

ATC CodeN/A